What foods should I eat for Thyroid Cancer (Nutritional Support)?

Brazil nuts (2/day) — selenium (200mcg); essential for thyroid peroxidase and deiodinase; reduces thyroid antibodies; most bioavailable selenium food source. Wild-caught fish (salmon, sardines) — omega-3 EPA/DHA; anti-inflammatory; selenium; iodine (avoid during LID preparation); eat freely outside RAI preparation period. Eggs — selenium, protein, vitamin D; complete nutrition; avoid during low-iodine diet preparation (egg yolks contain iodine)

What supplements help with Thyroid Cancer (Nutritional Support)?

Calcium citrate — 2,000–3,000mg daily in divided doses post-thyroidectomy; hypocalcemia prevention and treatment; citrate form preferred (does not require stomach acid); take 4+ hours after levothyroxine. Calcitriol (active vitamin D, 1,25-OH-D) — 0.25–1.0mcg twice daily for post-thyroidectomy hypoparathyroidism; prescribed by endocrinologist; monitor serum calcium closely. Vitamin D3 (cholecalciferol) — 5,000–10,000 IU daily for general thyroid cancer support; deficiency associated with worse prognosis; take 4+ hours after levothyroxine; target 60–80 ng/mL

What are the key nutrients for Thyroid Cancer (Nutritional Support)?

Key nutrients for Thyroid Cancer (Nutritional Support) include: Selenium, Calcium, Vitamin D3, Vitamin K2, Magnesium, Omega-3, Zinc, Curcumin, Iodine (carefully managed).

All Conditions

Cancer & Oncology Support

Thyroid Cancer (Nutritional Support)

Most common endocrine malignancy with excellent prognosis for differentiated types requiring iodine management, selenium optimization, and post-thyroidectomy nutritional support

SeleniumCalciumVitamin D3Vitamin K2MagnesiumOmega-3ZincCurcuminIodine (carefully managed)

Overview

Thyroid cancer is the most common endocrine malignancy (~586,000 new cases/year globally) and the fastest-rising cancer in the US over the past three decades (largely due to increased detection of small papillary cancers). Subtypes: papillary thyroid cancer (PTC, ~85% — excellent prognosis, 5-year survival >98%), follicular thyroid cancer (FTC, ~10% — good prognosis), medullary thyroid cancer (MTC, ~3–5% — RET mutations, familial in 25%), anaplastic thyroid cancer (ATC, <2% — extremely aggressive, median survival 3–5 months). Treatments: thyroidectomy (total or lobectomy — ATA guidelines favor lobectomy for low-risk PTC <4cm), radioactive iodine (RAI/I-131) ablation for differentiated thyroid cancer (DTC), TSH suppression with levothyroxine, lenvatinib and sorafenib (radioiodine-refractory DTC), vandetanib and cabozantinib (MTC), BRAF inhibitors (dabrafenib + trametinib for BRAF V600E+ ATC — FDA approved 2018), RET inhibitors (selpercatinib/Retevmo and pralsetinib/Gavreto — FDA approved 2020 for RET-mutant/fusion+ thyroid cancer). 2025–2026 advances: LIBRETTO-531 (2023) — selpercatinib superior to cabozantinib/vandetanib for RET-mutant MTC (PFS not reached vs 16.8 months; HR 0.28); CABINET trial (2024) — cabozantinib confirmed activity after RET inhibitor progression in MTC (6.4-month PFS vs 1.9 months placebo); fam-trastuzumab deruxtecan (T-DXd) for HER2-overexpressing thyroid cancer — DESTINY-PanTumor02 (2024): 51% ORR; spartalizumab + dabrafenib + trametinib triple combination for BRAF V600E+ ATC (ROAR basket trial: 69% ORR); tovorafenib (RAF inhibitor) for BRAF-altered thyroid cancer in trials; zanzalintinib (XL092) for radioiodine-refractory DTC in Phase II; comprehensive NGS molecular profiling now standard for all advanced thyroid cancers to guide targeted therapy selection. Nutritional rationale: low-iodine diet required 2 weeks before RAI; post-thyroidectomy hypoparathyroidism causes hypocalcemia requiring aggressive calcium/vitamin D supplementation; levothyroxine absorption is affected by calcium, iron, soy, and fiber timing; selenium is essential for thyroid peroxidase and deiodinase enzymes.

Evidence highlight: LIBRETTO-531 (2023): selpercatinib superior to cabozantinib/vandetanib for RET-mutant MTC — PFS not reached vs 16.8 months (HR 0.28; Hadoux et al., 2023). CABINET trial (2024): cabozantinib improved PFS after RET inhibitor progression in MTC (6.4 vs 1.9 months). DESTINY-PanTumor02 (2024): T-DXd achieved 51% ORR in HER2-overexpressing thyroid cancer. Spartalizumab + dabrafenib + trametinib: 69% ORR in BRAF V600E+ ATC (ROAR trial). SELECT trial: lenvatinib 65% ORR, 18.3-month PFS in radioiodine-refractory DTC (Schlumberger et al., 2015). Selenium 200mcg/day reduces thyroid antibodies (Toulis et al., 2010). Post-thyroidectomy hypocalcemia in 20–30% — aggressive calcium/calcitriol is standard of care.

Core Nutrition Principles

1Low-iodine diet (LID) is mandatory for 2 weeks before radioactive iodine (RAI) therapy — maximizes RAI uptake by thyroid remnant and metastases; <50mcg iodine/day
2Post-thyroidectomy hypoparathyroidism (temporary or permanent) causes hypocalcemia — aggressive calcium (2,000–3,000mg/day) and vitamin D3 (calcitriol) supplementation is critical
3Selenium is essential for thyroid peroxidase (TPO) and deiodinase enzymes — deficiency impairs thyroid hormone metabolism; selenomethionine 200mcg/day supports residual thyroid tissue and reduces thyroiditis
4Levothyroxine absorption is significantly impaired by calcium, iron, soy, fiber, and coffee — all must be taken at least 4 hours after levothyroxine
5TSH suppression with levothyroxine increases bone turnover and cardiovascular risk — calcium, vitamin D3, and vitamin K2 are essential for bone protection
6Cruciferous vegetables contain goitrogens (glucosinolates) that inhibit thyroid iodine uptake — cooking deactivates goitrogens; moderate cooked cruciferous intake is safe
7Iodine status must be carefully managed — both deficiency and excess can impair thyroid function; avoid iodine supplements and high-iodine foods except when specifically indicated
8Vitamin D deficiency is associated with increased thyroid cancer risk and worse prognosis — supplementation supports immune surveillance and treatment response

Priority Foods

Brazil nuts (2/day) — selenium (200mcg); essential for thyroid peroxidase and deiodinase; reduces thyroid antibodies; most bioavailable selenium food source
Wild-caught fish (salmon, sardines) — omega-3 EPA/DHA; anti-inflammatory; selenium; iodine (avoid during LID preparation); eat freely outside RAI preparation period
Eggs — selenium, protein, vitamin D; complete nutrition; avoid during low-iodine diet preparation (egg yolks contain iodine)
Dairy (milk, yogurt, cheese) — calcium; protein; vitamin D; critical for post-thyroidectomy hypocalcemia; avoid during low-iodine diet preparation
Cooked cruciferous vegetables (broccoli, cauliflower, Brussels sprouts) — cooking deactivates goitrogens; sulforaphane anti-tumor; safe in moderate amounts when cooked
Leafy greens (spinach, kale, arugula) — calcium, magnesium, vitamin K; bone health during TSH suppression; folate for DNA repair
Berries — antioxidants; anti-inflammatory; low iodine; safe during LID preparation
Legumes (lentils, chickpeas, black beans) — protein; fiber; zinc; magnesium; safe during LID preparation
Nuts and seeds (almonds, walnuts, pumpkin seeds) — magnesium, zinc, healthy fats; safe during LID preparation; avoid iodized salt-roasted varieties
Turmeric with black pepper — curcumin; anti-tumor; anti-inflammatory; safe during LID preparation
Green tea — EGCG; anti-tumor; antioxidant; safe during LID preparation

Core Supplements

Calcium citrate — 2,000–3,000mg daily in divided doses post-thyroidectomy; hypocalcemia prevention and treatment; citrate form preferred (does not require stomach acid); take 4+ hours after levothyroxine
Calcitriol (active vitamin D, 1,25-OH-D) — 0.25–1.0mcg twice daily for post-thyroidectomy hypoparathyroidism; prescribed by endocrinologist; monitor serum calcium closely
Vitamin D3 (cholecalciferol) — 5,000–10,000 IU daily for general thyroid cancer support; deficiency associated with worse prognosis; take 4+ hours after levothyroxine; target 60–80 ng/mL
Vitamin K2 (MK-7) — 200–400mcg daily; bone protection during TSH suppression; directs calcium to bone; reduces vascular calcification; take with D3
Selenium (selenomethionine) — 200mcg daily; thyroid peroxidase and deiodinase support; reduces thyroid antibodies; antioxidant; do not exceed 400mcg/day
Magnesium glycinate — 400–600mg daily; bone health; muscle function; sleep; take 4+ hours after levothyroxine
Omega-3 EPA/DHA — 2–3g daily; anti-inflammatory; cardiovascular protection (important during TSH suppression); anti-tumor
Zinc picolinate — 15–30mg daily; thyroid hormone synthesis; immune function; wound healing post-thyroidectomy; take 4+ hours after levothyroxine
Vitamin C — 1,000–2,000mg daily; antioxidant; immune support; collagen synthesis for wound healing post-thyroidectomy
Probiotics (30–50 billion CFU) — gut microbiome support; improve levothyroxine absorption; reduce autoimmune thyroid inflammation
Curcumin (phytosome) — 500–1,000mg twice daily; anti-tumor activity in thyroid cancer cell lines; NF-kB inhibition; anti-inflammatory
Melatonin — 5–20mg at bedtime; anti-tumor; antioxidant; improves sleep disrupted by TSH suppression; discuss with oncologist

Treatment Protocols

Total thyroidectomy — standard for PTC >4cm, bilateral disease, extrathyroidal extension, or high-risk features; lobectomy acceptable for low-risk PTC <4cm per 2015 ATA guidelines
Radioactive iodine (RAI/I-131) ablation — for intermediate/high-risk DTC post-thyroidectomy; requires 2-week low-iodine diet preparation; TSH stimulation (rhTSH injection or thyroid hormone withdrawal)
TSH suppression with levothyroxine — target TSH <0.1 mIU/L for high-risk DTC; 0.1–0.5 for intermediate-risk; 0.5–2.0 for low-risk; take on empty stomach 30–60 minutes before food
Lenvatinib (Lenvima) — multikinase inhibitor (VEGFR1-3, FGFR1-4, PDGFR, RET, KIT); FDA approved for radioiodine-refractory DTC; 65% ORR; SELECT trial
Sorafenib (Nexavar) — multikinase inhibitor; FDA approved for radioiodine-refractory DTC; 12.2% ORR; DECISION trial
Selpercatinib (Retevmo) — highly selective RET inhibitor; FDA approved 2020 for RET-mutant MTC and RET fusion+ thyroid cancer; 69% ORR in RET-mutant MTC; LIBRETTO-001 trial
Pralsetinib (Gavreto) — selective RET inhibitor; FDA approved 2020 for RET-mutant MTC; 60% ORR; ARROW trial
Vandetanib (Caprelsa) — RET/VEGFR/EGFR inhibitor; FDA approved for symptomatic/progressive MTC; 45% ORR
Cabozantinib (Cometriq) — RET/MET/VEGFR2 inhibitor; FDA approved for progressive MTC; 28% ORR; EXAM trial
Dabrafenib + trametinib — BRAF V600E + MEK inhibitor combination; FDA approved 2018 for BRAF V600E+ anaplastic thyroid cancer; 69% ORR; only approved treatment for ATC
NTRK inhibitors (larotrectinib, entrectinib) — tissue-agnostic FDA approval for NTRK fusion+ cancers; ~75% ORR in NTRK fusion+ thyroid cancer; molecular testing required
Fam-trastuzumab deruxtecan (T-DXd) — ADC for HER2-overexpressing thyroid cancer; DESTINY-PanTumor02 (2024): 51% ORR; emerging option for HER2+ DTC and ATC; requires HER2 testing
Cabozantinib second-line for MTC — CABINET trial (2024): 6.4-month PFS vs 1.9 months placebo after RET inhibitor progression; confirms cabozantinib as post-selpercatinib/pralsetinib standard
Spartalizumab + dabrafenib + trametinib — triple combination for BRAF V600E+ ATC; ROAR basket trial: 69% ORR; emerging standard for ATC with BRAF V600E mutation
Comprehensive NGS molecular profiling — standard for all advanced thyroid cancers; RET, BRAF, NTRK, ALK, RAS, HER2, IDH1, MET alterations guide targeted therapy selection
Endocrinology consultation — essential for levothyroxine dosing, TSH suppression monitoring, calcium/vitamin D management post-thyroidectomy, and RAI preparation
Bone density monitoring — DEXA scan at baseline and annually during TSH suppression; bisphosphonates or denosumab if osteoporosis develops
Vocal cord assessment — laryngoscopy before and after thyroidectomy; recurrent laryngeal nerve injury risk; speech therapy if hoarseness develops

Foods & Substances to Avoid

High-iodine foods during RAI preparation (2 weeks before) — seaweed (kelp, nori, wakame), iodized salt, seafood, dairy, eggs, bread made with iodate dough conditioners; target <50mcg iodine/day
Iodine supplements and multivitamins containing iodine — during RAI preparation and generally avoid excess iodine supplementation in thyroid cancer
Calcium and iron supplements within 4 hours of levothyroxine — significantly impair levothyroxine absorption; take at least 4 hours after levothyroxine
Soy products within 4 hours of levothyroxine — isoflavones impair levothyroxine absorption; take at least 4 hours after levothyroxine
Coffee and espresso within 1 hour of levothyroxine — reduces absorption by up to 25%; take levothyroxine 30–60 minutes before coffee
High-fiber foods (bran, psyllium) within 2 hours of levothyroxine — fiber binds levothyroxine and reduces absorption
Raw cruciferous vegetables in large amounts — goitrogens inhibit thyroid iodine uptake; cooking deactivates goitrogens; moderate cooked amounts are safe
Grapefruit with lenvatinib, sorafenib, cabozantinib, or vandetanib — CYP3A4 inhibition significantly increases drug levels and toxicity
St. John's Wort — CYP3A4 inducer; reduces lenvatinib, sorafenib, and cabozantinib efficacy
Alcohol — hepatotoxic; interacts with targeted therapy metabolism; impairs bone health during TSH suppression
Excess iodine supplementation (kelp supplements, high-dose iodine) — can cause both hypothyroidism and hyperthyroidism; avoid in thyroid cancer management

Get your personalized protocol

Take the full assessment to receive a protocol tailored to your specific symptoms and goals.

Start Assessment

Key Nutrients

SeleniumCalciumVitamin D3Vitamin K2MagnesiumOmega-3ZincCurcuminIodine (carefully managed)

Drug & Supplement Interactions

Some nutrients in this protocol may interact with medications. Always inform your prescriber of all supplements you take.

Vitamin KSignificant

•Warfarin (Coumadin) — vitamin K directly antagonizes warfarin; any change in intake requires INR monitoring
•Other anticoagulants (rivaroxaban, apixaban) — consult prescriber before supplementing
•Antibiotics — broad-spectrum antibiotics reduce gut bacteria that produce vitamin K2

Vitamin K2Significant

•Warfarin (Coumadin) — directly antagonizes anticoagulant effect; requires INR monitoring
•Other anticoagulants — consult prescriber; even small changes in K2 intake affect INR

IodineSignificant

•Thyroid medications (levothyroxine, methimazole) — iodine directly affects thyroid function; consult prescriber
•Amiodarone — contains high iodine; additive thyroid effects
•Lithium — combined use may cause hypothyroidism
•ACE inhibitors — potassium iodide may cause hyperkalemia

Vitamin AModerate

•Retinoids (isotretinoin, tretinoin) — additive toxicity risk; do not combine
•Warfarin — high-dose vitamin A may increase anticoagulant effect
•Orlistat — reduces fat-soluble vitamin absorption including vitamin A
•Cholestyramine — reduces vitamin A absorption

Vitamin B6Moderate

•Levodopa — B6 reduces drug effectiveness; avoid unless combined with carbidopa
•Phenytoin and phenobarbital — B6 may reduce drug levels

Vitamin B3Moderate

•Statins — combination increases risk of myopathy; use with caution
•Diabetes medications — high-dose niacin may impair glucose control
•Blood pressure medications — additive vasodilatory effect

SeleniumCaution

•Chemotherapy (cisplatin) — may reduce drug effectiveness; consult oncologist
•Anticoagulants — high doses may have mild antiplatelet effect
•Statins — may interact with statin metabolism at high doses

CalciumCaution

•Thyroid medications (levothyroxine) — calcium reduces absorption; separate by 4+ hours
•Antibiotics (tetracyclines, fluoroquinolones) — reduces antibiotic absorption; separate by 2+ hours
•Bisphosphonates — reduces absorption; separate by 2+ hours
•Iron supplements — compete for absorption; separate by 2+ hours
•Digoxin — high calcium may increase risk of digoxin toxicity
•Thiazide diuretics — may cause hypercalcemia when combined with calcium supplements

Vitamin DCaution

•Thiazide diuretics — combined with high-dose vitamin D may cause hypercalcemia
•Digoxin — hypercalcemia from excess vitamin D increases digoxin toxicity risk
•Corticosteroids — long-term use depletes vitamin D; supplementation is recommended
•Orlistat (weight loss drug) — reduces vitamin D absorption by up to 30%
•Cholestyramine — reduces vitamin D absorption; separate by 4+ hours
•Phenobarbital and phenytoin — accelerate vitamin D metabolism; may require higher doses

Vitamin ECaution

•Blood thinners (warfarin, aspirin) — additive antiplatelet effect at doses >400 IU/day
•Chemotherapy and radiation — high-dose vitamin E may reduce treatment effectiveness; consult oncologist
•Statins — may reduce statin effectiveness at very high doses
•Cyclosporine — may reduce drug levels
•Niacin — high-dose combination may reduce HDL-raising effect of niacin

Vitamin CCaution

•Warfarin — high doses (>1g/day) may reduce anticoagulant effect
•Chemotherapy — high-dose IV vitamin C may interact with certain agents; consult oncologist
•Iron supplements — significantly enhances iron absorption (beneficial in deficiency, caution in hemochromatosis)
•Statins — very high doses may reduce statin effectiveness
•Aluminum antacids — vitamin C increases aluminum absorption; avoid combination

Vitamin B12Caution

•Metformin — long-term use depletes B12; supplementation is recommended
•PPIs and H2 blockers — reduce B12 absorption; supplementation recommended with long-term use
•Chloramphenicol — may reduce B12 effectiveness

MagnesiumCaution

•Antibiotics (tetracyclines, fluoroquinolones) — magnesium reduces absorption; separate by 2+ hours
•Bisphosphonates (alendronate) — reduces absorption; separate by 2+ hours
•Diabetes medications — may enhance blood-glucose-lowering effect
•Diuretics — thiazide diuretics increase magnesium excretion; loop diuretics may deplete magnesium
•Digoxin — magnesium deficiency increases digoxin toxicity risk; supplementation may be protective
•Muscle relaxants — additive effect; may increase sedation

Magnesium ThreonateCaution

•Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
•Bisphosphonates — reduces absorption; separate by 2+ hours
•Diabetes medications — may enhance blood-glucose-lowering effect

Magnesium GlycinateCaution

•Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
•Diabetes medications — may enhance blood-glucose-lowering effect

Magnesium MalateCaution

•Antibiotics — reduces absorption; separate by 2+ hours
•Diabetes medications — may enhance blood-glucose-lowering effect

Omega-3Caution

•Blood thinners (warfarin, clopidogrel, aspirin) — additive antiplatelet effect; monitor INR at doses >2g/day
•Blood pressure medications — additive hypotensive effect at high doses (>3g/day)
•Cyclosporine — may reduce drug levels; monitor in transplant patients

ZincCaution

•Antibiotics (tetracyclines, fluoroquinolones) — zinc reduces antibiotic absorption; separate by 2+ hours
•Copper — high-dose zinc (>40mg/day) depletes copper; supplement 1–2mg copper per 30mg zinc
•Iron supplements — compete for absorption; separate by 2+ hours
•Penicillamine (for rheumatoid arthritis) — zinc reduces drug absorption
•Thiazide diuretics — increase zinc excretion

Zinc CarnosineCaution

•Antibiotics (tetracyclines, fluoroquinolones) — reduces antibiotic absorption; separate by 2+ hours
•Copper — high-dose zinc depletes copper

CurcuminCaution

•Blood thinners (warfarin, aspirin, clopidogrel) — additive antiplatelet effect at high doses
•Diabetes medications — may enhance blood-glucose-lowering effect
•Chemotherapy drugs — may interact with certain agents; consult oncologist
•Acid-reducing medications (PPIs, H2 blockers) — curcumin may reduce stomach acid
•Iron — may reduce iron absorption

This list covers common interactions and is not exhaustive. Consult a pharmacist or physician before combining supplements with prescription medications.